Wakefield Asset Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-15,328
Closed -$388K 237
2025
Q1
$388K Sell
15,328
-2,073
-12% -$54.2K 0.12% 168
2024
Q4
$462K Buy
17,401
+985
+6% +$26.7K 0.16% 138
2024
Q3
$475K Buy
16,416
+197
+1% +$5.75K 0.15% 131
2024
Q2
$454K Buy
+16,219
New +$447K 0.16% 131
2022
Q3
Sell
-2,163
Closed -$113K 197
2022
Q2
$113K Sell
2,163
-35,614
-94% -$1.81M 0.05% 165
2022
Q1
$1.96M Sell
37,777
-1,088
-3% -$56.5K 0.7% 45
2021
Q4
$2.29M Sell
38,865
-325
-0.8% -$16.1K 0.79% 40
2021
Q3
$1.69M Buy
39,190
+1,964
+5% +$87K 0.63% 55
2021
Q2
$1.46M Buy
+37,226
New +$1.45M 0.55% 61
2019
Q3
Sell
-101
Closed -$4K 192
2019
Q2
$4K Sell
101
-780
-89% -$31K ﹤0.01% 170
2019
Q1
$36K Sell
881
-8,173
-90% -$327K 0.01% 161
2018
Q4
$375K Sell
9,054
-1,271
-12% -$52.8K 0.16% 116
2018
Q3
$432K Buy
+10,325
New +$397K 0.17% 75

Other funds holding PFE

Wakefield Asset Management's PFE Position: Q2 2025 in Review

Wakefield Asset Management sold out of Pfizer (PFE) in Q2 2025, closing a stake of 15,328 shares — an estimated $388K sold.

Wakefield Asset Management first reported a position in PFE in Q3 2018 and held it in 13 quarters. The position peaked at $2.29M in Q4 2021. 2,809 funds tracked by Wall St. Rank hold PFE as of Q2 2025.

  • Wakefield Asset Management reported no remaining Pfizer position as of Q2 2025 after selling out during the quarter.
  • Wakefield Asset Management sold 15,328 Pfizer shares in Q2 2025, an estimated $388K.
  • Wakefield Asset Management first reported a position in Pfizer in Q3 2018 and held it in 13 quarters.
  • Wakefield Asset Management's Pfizer position peaked at $2.29M in Q4 2021.
  • 2,809 funds tracked by Wall St. Rank held Pfizer as of Q2 2025.

Based on Wakefield Asset Management's 13F filing for Q2 2025, filed 5 Aug 2025.